

Nonalcoholic Fatty Liver Disease (NAFLD) Market 2026

<https://marketpublishers.com/r/NEF1A974301CEN.html>

Date: January 2026

Pages: 223

Price: US\$ 2,999.00 (Single User License)

ID: NEF1A974301CEN

Abstracts

The Nonalcoholic Fatty Liver Disease (NAFLD) Market was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Nonalcoholic Fatty Liver Disease (NAFLD) Market.

This report delivers a comprehensive overview of the Nonalcoholic Fatty Liver Disease (NAFLD) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Nonalcoholic Fatty Liver Disease (NAFLD) Market. The Nonalcoholic Fatty Liver Disease (NAFLD) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Nonalcoholic Fatty Liver Disease (NAFLD) Market Scope:

By Drug Class

Antioxidants

Lipid-Lowering Drugs

Insulin sensitizers

Pentoxifylline

Angiotensin Receptor Blockers

Others

By Disease Stage

Non-Alcoholic Steatohepatitis (NASH)

Cirrhosis

Fibrosis

By Route of Administration

Injectable

Oral

Other

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Key Players

Pfizer Inc.

AstraZeneca

Novartis AG

Takeda Pharmaceutical Company Limited.

Intercept Pharmaceuticals, Inc.

F. Hoffmann-La Roche AG

Merck & Co., Inc.

AbbVie Inc.

Gilead Sciences, Inc.

Akero Therapeutics, Inc.

Major Highlights

This report delivers a comprehensive overview of the Nonalcoholic Fatty Liver Disease (NAFLD) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Nonalcoholic Fatty Liver Disease (NAFLD) Market. The Nonalcoholic Fatty Liver Disease (NAFLD) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for —.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Drug Class
- 3.2. Snippet by Disease Stage
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. High Prevalence of Condition
 - 4.1.1.2. XX
 - 4.1.2. Restraints
 - 4.1.2.1. Stringent Regulatory Authorities
 - 4.1.2.2. XX
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Patent Analysis
- 5.7. Pipeline Analysis
- 5.8. Epidemiology

5.9. SWOT Analysis

5.10. DMI Opinion

6. COVID-19 ANALYSIS

6.1. Analysis of COVID-19

6.1.1. Scenario Before COVID

6.1.2. Scenario During COVID

6.1.3. Scenario Post COVID

6.2. Pricing Dynamics Amid COVID-19

6.3. Demand-Supply Spectrum

6.4. Government Initiatives Related to the Market During Pandemic

6.5. Manufacturers Strategic Initiatives

6.6. Conclusion

7. BY DRUG CLASS

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

7.1.2. Market Attractiveness Index, By Drug Class

7.2. Antioxidants*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Lipid-Lowering Drugs

7.4. Insulin sensitizers

7.5. Pentoxifylline

7.6. Angiotensin Receptor Blockers

7.7. Others

8. BY DISEASE STAGE

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage

8.1.2. Market Attractiveness Index, By Disease Stage

8.2. Non-Alcoholic Steatohepatitis (NASH)*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Cirrhosis

8.4. Fibrosis

9. BY ROUTE OF ADMINISTRATION

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9.1.2. Market Attractiveness Index, By Route of Administration

9.2. Injectable*

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.3. Oral

9.4. Other

10. BY DISTRIBUTION CHANNEL

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.1.2. Market Attractiveness Index, By Distribution Channel

10.2. Hospital Pharmacies*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

10.3. Retail Pharmacies

10.4. Online Pharmacies

10.5. Others

11. BY REGION

11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

11.1.2. Market Attractiveness Index, By Region

11.2. North America

11.2.1. Introduction

11.2.2. Key Region-Specific Dynamics

11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage

11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.2.7.1. U.S.

11.2.7.2. Canada

11.2.7.3. Mexico

11.3. Europe

11.3.1. Introduction

11.3.2. Key Region-Specific Dynamics

11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage

11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.3.7.1. Germany

11.3.7.2. UK

11.3.7.3. France

11.3.7.4. Italy

11.3.7.5. Spain

11.3.7.6. Rest of Europe

11.4. South America

11.4.1. Introduction

11.4.2. Key Region-Specific Dynamics

11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage

11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.4.7.1. Brazil

11.4.7.2. Argentina

11.4.7.3. Rest of South America

11.5. Asia-Pacific

11.5.1. Introduction

11.5.2. Key Region-Specific Dynamics

11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage

11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

- 11.5.7.1. China
- 11.5.7.2. India
- 11.5.7.3. Japan
- 11.5.7.4. Australia
- 11.5.7.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
 - 11.6.1. Introduction
 - 11.6.2. Key Region-Specific Dynamics
 - 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
 - 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. COMPETITIVE LANDSCAPE

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

- 13.1. Pfizer Inc.*
 - 13.1.1. Company Overview
 - 13.1.2. Product Portfolio and Description
 - 13.1.3. Financial Overview
 - 13.1.4. Key Developments
- 13.2. AstraZeneca
- 13.3. Novartis AG
- 13.4. Takeda Pharmaceutical Company Limited.
- 13.5. Intercept Pharmaceuticals, Inc.
- 13.6. F. Hoffmann-La Roche AG
- 13.7. Merck & Co., Inc.
- 13.8. AbbVie Inc.
- 13.9. Gilead Sciences, Inc.
- 13.10. Akeru Therapeutics, Inc. (LIST NOT EXHAUSTIVE)

14. APPENDIX

14.1. About Us and Services

14.2. Contact Us

I would like to order

Product name: Nonalcoholic Fatty Liver Disease (NAFLD) Market 2026

Product link: <https://marketpublishers.com/r/NEF1A974301CEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NEF1A974301CEN.html>